Sugi Predict

Sugi Predict / Compounds / SCHEMBL1989347

SCHEMBL1989347

SCHEMBL1989347

CCOC[C@@H](CO)NC(=O)OC(C)(C)C

nearest known ligand 0.42

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.42
▸ CA2 P00918 1/20 0.42
▸ CA7 P43166 1/20 0.42
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ CTSK P43235 9/20 0.40
▸ CTSS P25774 5/20 0.40
▸ ATM Q13315 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.37
▸ SYK P43405 1/20 0.36
▸ PPARA Q07869 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1989346 1.00 CA1 (0.42) CA1CA2CA7CYP1A2CYP2C9
SCHEMBL1991498 0.85 CA1 (0.41) CA1CA2CA7CYP1A2CYP2C9
SCHEMBL1991496 0.85 CA1 (0.41) CA1CA2CA7CYP1A2CYP2C9
SCHEMBL13942942 0.84 PLA2G2C (0.48) CTSKCTSS
SCHEMBL8298404 0.84 PLA2G2C (0.48) CTSKCTSS
SCHEMBL7498266 0.84 CA1 (0.41) CA1CA2CA7CTSKCTSS
SCHEMBL90567 0.84 AAK1 (0.51) CA1CA2CA7CTSKCTSS
SCHEMBL26655983 0.84 CA1 (0.41) CA1CA2CA7CTSKCTSS
SCHEMBL26655989 0.84 CA1 (0.41) CA1CA2CA7CTSKCTSS
SCHEMBL2861782 0.84 CA1 (0.52) CA1CA2CA7CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 — — US disclosed
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 — — US disclosed
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES WELLS THERAPEUTICS, INC. 2023-09-21 — — US disclosed
US-20220306634-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA SAN DIEGO, INC. 2022-09-29 — — US disclosed
EP-3825316-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2021-05-26 — — EP disclosed
EP-3489236-B1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICALS CO (JP) 2020-09-30 — — EP disclosed
EP-3489236-A1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES Takeda Pharmaceutical Company Limited (JP) 2019-05-29 — — EP disclosed
EP-3489236-A1 PROCESS FOR THE PREPARATION OF FUSED HETEROAROMATIC PYRROLIDINONES Takeda Pharmaceutical Company Limited (JP) 2019-05-29 — — EP disclosed
EP-2902392-B1 Fused heteroaromatic pyrrolidinones as syk inhibitors TAKEDA PHARMACEUTICALS CO (JP) 2018-10-17 — — EP disclosed
US-20180141951-A1 FUSED HETEROAROMATIC PYRROLIDINONES CALITHERA BIOSCIENCES, INC. 2018-05-24 — — US disclosed
US-20130245031-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2013-09-19 — — US disclosed
US-20130245031-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) 2013-09-19 — — US disclosed
US-8440689-B2 Fused heteroaromatic pyrrolidinones TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-14 — — US disclosed
US-8440689-B2 Fused heteroaromatic pyrrolidinones TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-14 — — US disclosed
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-09 — — US disclosed
US-20110152273-A1 FUSED HETEROAROMATIC PYRROLIDINONES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-23 — — US disclosed
US-7872004-B2 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2011-01-18 — — US disclosed
US-7872004-B2 6-(heterocyclyl-substituted benzyl)-4-oxoquinoline compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2011-01-18 — — US disclosed
US-20080207618-A1 6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor JAPAN TOBACCO INC. (JP) 2008-08-28 — — US disclosed
US-20080207618-A1 6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor JAPAN TOBACCO INC. (JP) 2008-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306634-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN CA1 3703/4885CA2 4062/4885CA7 3312/4885
US-20180141951-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN CA1 3703/4885CA2 4062/4885CA7 3312/4885
US-20130116260-A1 FUSED HETEROAROMATIC PYRROLIDINONES AS SYK INHIBITORS SYK, BTK, LYN CA1 3993/4885CA2 4156/4885CA7 3775/4885
US-20130245031-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN CA1 3703/4885CA2 4062/4885CA7 3312/4885
US-20110152273-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN CA1 3703/4885CA2 4062/4885CA7 3312/4885
US-20080207618-A1 6- (Heterocyclyl-substituted Benzyl) -4-Oxoquinoline Compound and Use Thereof as HIV Integrase Inhibitor CDK6, INTS6, TYMP CA1 4608/4885CA2 3909/4885CA7 2769/4885
US-20230295171-A1 FUSED HETEROAROMATIC PYRROLIDINONES SYK, ZAP70, LYN CA1 3703/4885CA2 4062/4885CA7 3312/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.